Mika Mizoguchi
Wakayama Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mika Mizoguchi.
Cancer Science | 2014
Yuko Tanizaki; Aya Kobayashi; Saori Toujima; Michihisa Shiro; Mika Mizoguchi; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Osamu Takikawa; Kazuhiko Ino
Indoleamine 2,3‐dioxygenase (IDO) is a tryptophan‐catabolizing enzyme that has immunoregulatory functions. Our prior study showed that tumoral IDO overexpression is involved in disease progression and impaired patient survival in human ovarian cancer, although its mechanism remains unclear. The purpose of the present study is to clarify the role of IDO during the process of peritoneal dissemination of ovarian cancer. Indoleamine 2,3‐dioxygenase cDNA was transfected into the murine ovarian carcinoma cell line OV2944‐HM‐1, establishing stable clones of IDO‐overexpressing cells (HM‐1‐IDO). Then HM‐1‐IDO or control vector‐transfected cells (HM‐1‐mock) were i.p. transplanted into syngeneic immunocompetent mice. The HM‐1‐IDO‐transplanted mice showed significantly shortened survival compared with HM‐1‐mock‐transplanted (control) mice. On days 11 and 14 following transplantation, the tumor weight of peritoneal dissemination and ascites volume were significantly increased in HM‐1‐IDO‐transplanted mice compared with those of control mice. This tumor‐progressive effect was coincident with significantly reduced numbers of CD8+ T cells and natural killer cells within tumors as well as increased levels of transforming growth factor‐β and interleukin‐10 in ascites. Finally, treatment with the IDO inhibitor 1‐methyl‐tryptophan significantly suppressed tumor dissemination and ascites with reduced transforming growth factor‐β secretion. These findings showed that tumor‐derived IDO promotes the peritoneal dissemination of ovarian cancer through suppression of tumor‐infiltrating effector T cell and natural killer cell recruitment and reciprocal enhancement of immunosuppressive cytokines in ascites, creating an immunotolerogenic environment within the peritoneal cavity. Therefore, IDO may be a promising molecular target for the therapeutic strategy of ovarian cancer.
Journal of Obstetrics and Gynaecology Research | 2014
Mika Mizoguchi; Sawako Minami; Madoka Yamamoto; Yuko Tanizaki; Aya Kobayashi; Kazuhiko Ino
Steroid cell tumor, not otherwise specified, is a rare type of ovarian sex cord‐stromal tumor with malignant potential. Some of these tumors produce testosterone. We describe a case of steroid cell tumor of the ovary associated with virilization. A 23‐year‐old nulliparous woman was found to have an ovarian tumor when she visited her primary doctor for virilization and oligomenorrhea. Magnetic resonance imaging revealed a solid left ovarian tumor 40 mm in size. Her laboratory data revealed elevated testosterone with normal levels of gonadotropins, estradiol, dehydroepiandrosterone sulfate and cortisol. She underwent left adnexectomy. On histopathologic and immunohistochemical analyses, the tumor was diagnosed as steroid cell tumor, not otherwise specified, without malignant behavior. After removal of the tumor, serum testosterone level decreased, and there have been no signs of recurrence.
Journal of Obstetrics and Gynaecology Research | 2017
Sakiko Nanjo; Sawako Minami; Mika Mizoguchi; Madoka Yamamoto; Tamaki Yahata; Saori Toujima; Michihisa Shiro; Aya Kobayashi; Yasuteru Muragaki; Kazuhiko Ino
We aimed to investigate maternal serum angiogenic marker profiles within 1 week prior to delivery in cases of gestational hypertension (GH), pre‐eclampsia (PE), and/or fetal growth restriction (FGR) with different clinical conditions.
Molecular and Clinical Oncology | 2017
Aya Kobayashi; Tamaki Yahata; Sakiko Nanjo; Mika Mizoguchi; Madoka Yamamoto; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Kazuhiko Ino
Large-cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine tumor. LCNECs arising from the genital organs are highly malignant and rare, with <20 cases of LCNEC developing from the uterine endometrium reported to date. We herein present the case of a patient with LCNEC of the endometrium. The patient was a 52-year-old woman, who exhibited lower abdominal pain and rapid uterine enlargement during outpatient treatment for uterine myoma. The endometrial biopsy suggested a diagnosis of poorly differentiated carcinoma or carcinosarcoma. Based on magnetic resonance imaging and positron emission tomography/computed tomography, endometrial stromal sarcoma was suspected. The serum lactate dehydrogenase level was abnormally high. Due to the suspicion of stage IIIC malignant tumor of the uterine corpus, surgery was performed. The pathological diagnosis was stage IIIC2 LCNEC of the endometrium. Recurrence occurred in the vaginal stump, and concurrent chemoradiotherapy (CCRT) was initiated 1 month after the surgery. The residual lesions markedly shrank, but metastasis to the upper abdominal region and cervix subsequently developed. CCRT was attempted, but the associated adverse effects were severe and was switched to palliative treatment. The patient eventually succumbed to the disease 309 days after surgery.
Endocrinology | 2017
Madoka Yamamoto; Midori Ikezaki; Saori Toujima; Naoyuki Iwahashi; Mika Mizoguchi; Sakiko Nanjo; Sawako Minami; Yoshito Ihara; Kazuhiko Ino
Calreticulin (CRT), a molecular chaperone in the endoplasmic reticulum (ER), plays a variety of roles in cell growth, differentiation, apoptosis, immunity, and cancer biology. It has been reported that CRT is expressed in the human placenta, although its function in placental development is poorly understood. Appropriate invasion of extravillous trophoblasts (EVTs) into the maternal decidua is necessary for successful pregnancy. The objective of the present study was to investigate the expression and functional role of CRT in EVTs using the human EVT cell line HTR8/SVneo, in which CRT gene expression was knocked down. We found that CRT was highly expressed in the human placenta in the early stage of pregnancy and localized to the EVTs. CRT knockdown markedly suppressed the invasion ability of HTR8/SVneo cells. Furthermore, the adhesion to fibronectin was suppressed in the CRT-knockdown cells via the dysfunction of integrin α5β1. In the CRT-knockdown cells, terminal sialylation and fucosylation were decreased, and the core galactose-containing structure was increased in the N-glycans of integrin β1. In addition, the expression levels of several critical glycosyltransferases were changed in the CRT-knockdown cells, consistent with the changes in the N-glycans. These results showed that CRT regulates the function of integrin β1 by affecting the synthesis of N-glycans in HTR8/SVneo cells. Collectively, the results of the present study demonstrate that the ER chaperone CRT plays a regulatory role in the invasion of EVTs, suggesting the importance of CRT expression in placental development during early pregnancy.
Molecular and Clinical Oncology | 2016
Tamaki Yahata; Shigetaka Yagi; Yasushi Mabuchi; Yuko Tanizaki; Aya Kobayashi; Madoka Yamamoto; Mika Mizoguchi; Sakiko Nanjo; Michihisa Shiro; Nami Ota; Sawako Minami; Masaki Terada; Kazuhiko Ino
Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health | 2018
Sakiko Nanjo; Madoka Yamamoto; Mika Mizoguchi; Tamaki Yahata; Sawako Minami; Kazuhiko Ino
日本産科婦人科學會雜誌 | 2016
Naoyuki Iwahashi; Madoka Yamamoto; Mika Mizoguchi; Sakiko Nanjyo; Aya Kobayashi; Yuko Tanizaki; Michihisa Shiro; Nami Ota; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Kazuhiko Ino
Placenta | 2016
Mika Mizoguchi; Tamaki Yahata; Sakiko Nanjo; Madoka Yamamoto; Aya Kobayashi; Mizuho Nosaka; Yuko Ishida; Yumi Kuninaka; Akihiko Kimura; Sawako Minami; Naofumi Mukaida; Toshikazu Kondo; Kazuhiko Ino
Placenta | 2016
Sakiko Nanjo; Ayaha Matsushita; Tamaki Yahata; Mika Mizoguchi; Madoka Yamamoto; Nami Ota; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Yasuteru Muragaki; Kazuhiko Ino